Table 1.
Demographic and clinical characteristics of all PrCa patients (middle aged and elderly).
| Overall (n = 502) | Middle aged (n = 367) | Elderly (n = 135) | Pa) | |
|---|---|---|---|---|
| Age, mean (SD) | 59.7 (7.2) | 56.8 (4.9) | 68.6 (3.1) | <0.01 |
| BMI, mean, (SD) | 27.8 (4.0) | 27.9 (4.2) | 27.5 (3.8) | 0.35 |
| Race, n (%) | ||||
| Caucasian | 450 (89.6) | 332 (90.5) | 118 (87.4) | 0.14 |
| African American | 43 (8.6) | 31 (8.4) | 12 (8.9) | |
| Asian | 9 (1.8) | 4 (1.1) | 5 (3.7) | |
| Preoperative PSA, median (IQR) | 4.7 (2.7) | 4.7 (2.8) | 5.0 (2.5) | 0.34b) |
| Total testosterone, n (%) | ||||
| Low | 33 (6.6) | 26 (7.1) | 7 (5.2) | 0.45 |
| Normal | 469 (93.4) | 341 (92.9) | 128 (94.8) | |
| Free testosterone, n (%) | ||||
| Low | 102 (20.3) | 75 (20.4) | 27 (20) | 0.91 |
| Normal | 400 (79.7) | 292 (79.6) | 108 (80) | |
| Clinical stage, n (%) | ||||
| T1 | 438 (87.2) | 323 (88) | 115 (85.2) | 0.39 |
| T2 | 64 (12.7) | 44 (12) | 20 (14.8) | |
| Prostate biopsy | ||||
| Total cores, mean (SD) | 12 (0.3) | 12 (0.3) | 12 (0.3) | 0.72 |
| Positive cores, mean (SD) | 3.3 (2.3) | 3.2 (2.4) | 3.5 (2.3) | 0.32 |
| Gleason score, n (%) | ||||
| ≤6 | 266 (53) | 210 (57.2) | 56 (41.5) | <0.01 |
| 7 | 186 (37) | 124 (33.8) | 62 (45.9) | |
| ≥8 | 50 (10) | 33 (9) | 17 (12.6) | |
| Surgical specimen | ||||
| Gleason score, n (%) | ||||
| ≤6 | 154 (30.7) | 120 (32.7) | 34 (25.2) | 0.04 |
| 7 | 307 (61.1) | 223 (60.8) | 84 (62.2) | |
| ≥8 | 41 (8.2) | 24 (6.5) | 17 (12.6) | |
| Prostate volume, mean (SD) | 47 (18.2) | 45.4 (16.8) | 51.9 (21) | 0.002 |
| Tumor volume, mL (SD) | 6.7 (5.8) | 6.5 (5.9) | 7.6 (5.7) | 0.055 |
| Stage, n (%) | ||||
| T2 | 388 (77.3) | 293 (79.8) | 95 (70.4) | 0.03 |
| T3 | 114 (22.7) | 74 (20.2) | 40 (29.6) | |
| Positive surgical margins, n (%) | 96 (19.1) | 67 (18.3) | 26 (19.3) | 0.79 |
| Positive lymph nodes, n (%) | 10 (2) | 8 (2.2) | 2 (1.5) | 0.62 |
BMI, body mass index; IQR, interquartile range; PrCa, prostate cancer; PSA, prostate-specific antigen; SD, standard deviation.
a)
Comparing middle-aged and elderly patients only.
b)
We used Wilcoxon sign-rank tests given the non-normal distribution.